$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Coated tablets

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-009/16
  • A61K-009/20
  • A61K-009/48
  • A61K-009/50
출원번호 US-0428007 (2003-05-02)
등록번호 US-8586094 (2013-11-19)
발명자 / 주소
  • Vachon, Michael
  • Awadesh, Mishra K.
  • Snow, Robert A.
  • Guivarc'H, Pol-Henri
출원인 / 주소
  • Jagotec AG
대리인 / 주소
    Liberto, Esq., Muriel
인용정보 피인용 횟수 : 0  인용 특허 : 188

초록

Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excip

대표청구항

1. A pharmaceutically acceptable oral dosage form of fenofibrate comprising fenofibrate present in an amount of from about 15% w/w to about 20% w/w of the dosage form; phospholipid present in an amount of from about 1% w/w to about 8% w/w of the dosage form;a buffer salt present in an amount of from

이 특허에 인용된 특허 (188)

  1. Bertolini Girogio (Milan ITX) Casagrande Cesare (Arese ITX) Santangelo Francesco (Milan ITX), 1,2,3-triazole compounds active as inhibitors of the enzyme HMG-CoA reductase and pharmaceutical compositions containing.
  2. Glamkowski Edward J. (Warren NJ) Fortunato James M. (North Wales PA), 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof.
  3. Glen John Baird (Macclesfield EN) James Roger (Macclesfield EN), 2,6-Diisopropylphenol as an anaesthetic agent.
  4. Joshua Henry (Staten Island NY) Wilson Kenneth E. (Westfield NJ) Schwartz Michael S. (Glenside PA) Lee Ta J. (Lansdale PA) Stokker Gerald E. (Gwynedd Valley PA), 3-keto HMG-COA reductase inhibitors.
  5. Joshua Henry (Staten Island NY) Wilson Kenneth E. (Westfield NJ) Schwartz Michael S. (Glenside PA) Lee Ta J. (Lansdale PA) Stokker Gerald E. (Gwynedd Valley PA), 3-keto HMG-CoA reductase inhibitors.
  6. Lee Ta J. (Lansdale PA) Holtz Wilbur J. (Lansdale PA), 4-Substituted HMG-CoA reductase inhibitors.
  7. Lee Ta J. (Lansdale PA) Holtz Wilbur J. (Lansdale PA), 4-substituted HMG-CoA reductase inhibitors.
  8. Duggan Mark E. (Wynnewood PA) Hartman George D. (Lansdale PA), 5-Oxygenated HMG-COA reductase inhibitors.
  9. Duggan Mark E. (Wynnewood PA) Hartman George D. (Lansdale PA), 5-oxa, 5-thia, 5-aza HmG-CoA reductase inhibitors.
  10. Duggan Mark E. (Wynnewood PA) Hartman George D. (Lansdale PA), 5-oxygenated HMG-CoA reductase inhibitors.
  11. Chucholowski Alexander W. (Ypsilanti MI) Roth Bruce D. (Ann Arbor MI) Sliskovic Drago R. (Ypsilanti MI), 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis.
  12. Chucholowski Alexander W. (Ypsilanti MI) Creswell Mark W. (Chelsea MI) Roth Bruce D. (Ann Arbor MI) Sliskovic Drago R. (Ypsilanti MI), 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis.
  13. Chucholowski Alexander W. (Ypsilanti MI) Creswell Mark W. (Chelsea MI) Roth Bruce D. (Ann Arbor MI) Sliskovic Drago R. (Ypsilanti MI), 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis.
  14. Picard Joseph A. (Ann Arbor MI) Sliskovic Drago R. (Ypsilanti MI), 6-(2-(2-(Substituted amino)-3-quinolinyl) ethenyl and ethyl) tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol b.
  15. Jendralla Heiner (Frankfurt am Main DEX) Wess Gnther (Erlensee DEX) Bartmann Wilhelm (Bad Soden am Taunus DEX) Beck Gerhard (Frankfurt am Main DEX), 6-phenoxymethyl-4-hydroxytetrahydropyran-2-ones and 6-thiphenoxymethyl-4-hydroxytetrahydropyran-2-ones and the correspon.
  16. Duggan Mark E. (Wynnewood PA) Halczenko Wasyl (Hatfield PA) Hartman George D. (Lansdale PA), 7-substituted HMG-CoA reductase inhibitors.
  17. Kesseler Kurt (Soden am Taunus DEX) Bartmann Wilhelm (Soden am Taunus DEX) Wess Gnther (Erlensee DEX) Granzer Ernold (Kelkheim DEX), 7-substituted derivatives of 3,5-dihydroxyhept-6-ynoic acids and corresponding lactones and their use as hypercholeserol.
  18. Yagi Kunio (Nagoya JPX) Kojma Nakao (Kani JPX) Takano Makoto (Ibaragi JPX), Adriamycin-entrapping liposome preparation.
  19. Yapel ; Jr. Anthony F. (Saint Paul MN), Albumin medicament carrier system.
  20. Onishi Janet C. (Mountainside NJ) Patchett Arthur A. (Westfield NJ), Antifungal compositions and method of controlling mycotic infections.
  21. Hoffman William F. (Lansdale PA) Smith Robert L. (Lansdale PA) Willard Alvin K. (Wilmington DE), Antihypercholesterolemic compounds.
  22. Bertolini Giorgio (Sesto San Giovanni ITX) Casagrande Cesare (Arese ITX) Santangelo Francesco (Milano ITX), Beazimidazole compounds active as inhibitors of the cholesterol biosynthesis.
  23. Paugh Edward C., Belt clip.
  24. Morris Robert L. (Wayne PA) Barton Jeffrey N. (Philadelphia PA), Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors.
  25. Haga Takahiro (Kusatsu JPX) Yamada Nobutoshi (Moriyama JPX) Sugi Hideo (Moriyama JPX) Koyanagi Toru (Kyoto JPX) Kondo Nobuo (Daito JPX) Nakajima Tsunetaka (Kashiwara JPX) Watanabe Masahiro (Akashi JP, Benzoyl urea compounds, process for their production, and antitumorous compositions containing them.
  26. Roth Bruce D. (Ann Arbor MI), Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis.
  27. Roth Bruce D. (Ann Arbor MI), Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis.
  28. Couvreur Patrick (8 ; Avenue de la Foret 1970 Wezembeek-Oppem BEX) Roland Michel (38 ; rue Tomberg 1150 Bruxelles BEX) Speiser Peter (26Wassbergerstrasse 8127 Forch CHX), Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them.
  29. Helms Gregory L. (Fanwood NJ) Horn Wendy S. (Westfield NJ) Jones E. Tracy T. (Edison NJ) Linemeyer David L. (Westfield NJ), Cholesterol lowering agents.
  30. Chiang Yuan-Ching P. (Scotch Plains NJ), Cholesterol lowering compounds.
  31. Dufresne Claude (East Brunswick NJ), Cholesterol lowering compounds.
  32. Harris Guy H. (Cranford NJ) Joshua Henry (Staten Island NY) Zink Deborah L. (Manalapan NJ), Cholesterol lowering compounds.
  33. Joshua Henry (Staten Island NY) Harris Guy H. (Cranford NJ), Cholesterol lowering compounds.
  34. MacConnell John G. (Watchung NJ) Arison Byron H. (Watchung NJ) Doss George A. (Westfield NJ) Monaghan Richard L. (Somerset NJ), Cholesterol lowering compounds.
  35. Byrne Kevin M. (West Trenton NJ) Chen Shieh-Shung T. (Morganville NJ) Kaplan Louis (New City NY) MacConnell John G. (Westfield NJ) Petuch Brian R. (Florence NJ) White Raymond F. (Palmyia VA) Arison B, Cholesterol lowering compounds produced by directed biosynthesis.
  36. Berger Gregory D. (Belle Mead NJ) Bergstrom James D. (Neshanic NJ) Biftu Tesfaye (Westfield NJ) Bugianesi Robert L. (Colonia NJ) Burk Robert M. (Laguna Beach CA) Girotra Narindar N. (Old Bridge NJ) K, Cholesterol-lowering agents.
  37. Dufresne Claude (East Brunswick NJ) Guarro Josep (Tarragona NJ ESX) Huang Leeyuan (Watchung NJ) Kong Yu L. (Edison NJ) Lingham Russell B. (Watchung NJ) Meinz Maria S. (Somerset NJ) Silverman Keith C., Cholesterol-lowering agents.
  38. Edgar Alan Dunlap,FRX ; Bellamy Fran.cedilla.ois,FRX, Combination of fenofibrate and vitamin E, and method of use of same in therapeutic treatments.
  39. Parikh Indu ; Selvaraj Ulagaraj, Composition and method of preparing microparticles of water-insoluble substances.
  40. Parikh Indu,CAX ; Selvaraj Ulagaraj, Composition and method of preparing microparticles of water-insoluble substances.
  41. Bertolini Giorgio (Sesto San Giovanni) Casagrande Cesare (Arese) Santangelo Francesco (Milan ITX), Compounds active as inhibitors of the cholesterol biosynthesis.
  42. Bloch Rene (Savion IL) Kedem Ora (Rehovoth IL) Lobel Ester (Hulon IL), Controlled drug releasing preparations.
  43. Kurihara Kozo (Tokyo JPX) Murano Masaru (Tokyo JPX), Cyclosporin formulations of mono or diglyceride fatty acid.
  44. Woo Jong Soo (Kyunggi-do KRX), Cyclosporin soft capsule composition.
  45. Woo Jong S. (Kyunggi-do KRX), Cyclosporin-containing soft capsule compositions.
  46. Woo Jong S. (Kyunggi-do KRX), Cyclosporin-containing soft capsule compositions.
  47. Lacy Jonathan E.,GBX ; Embleton Jonathan K.,GBX ; Perry Elizabeth A.,GBX, Delivery systems for hydrophobic drugs.
  48. Lacy Jonathan Ernest (Swindon GBX) Embleton Jonathan Kenneth (Berkshire GBX), Delivery systems for hydrophobic drugs.
  49. Ecanow Bernard (Wilmette IL), Drug delivery compositions and methods.
  50. Mizushima Yutaka (Kawasaki JPX) Uchida Katsuhiro (Kyoto JPX) Masumoto Shozoh (Shiga JPX) Tohno Masao (Otsu JPX) Hashimoto Yoshinobu (Fujisawa JPX) Yokoyama Kazumasa (Toyonaka JPX) Okamoto Hiroyuki (A, Ester of flurbiprofen and emulsion containing the same.
  51. Mizushima Yutaka (Kawasaki JPX) Yokoyama Kazumasa (Toyonaka JPX) Nabeta Kiichiro (Sennan JPX) Yamada Noboru (Ashiya JPX) Suyama Tadakazu (Tsuzuki JPX), Fat emulsion containing steroid.
  52. Okamoto Hiroyuki (Akashi JPX) Tsuda Yoshio (Kyoto JPX) Yokoyama Kazumasa (Toyonaka JPX), Fat emulsion for intravenous injection.
  53. Stamm Andre,FRX ; Seth Pawan, Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it.
  54. Illig Kathleen J. (Phoenixville PA) Sarpotdar Pramod (Malvern PA), Formulations comprising olin 10-G to prevent particle aggregation and increase stability.
  55. Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants.
  56. Vickers Stanley (Perkasie PA), HMG-COA reductase inhibitor metabolites.
  57. Neuenschwander Kent W. (Ambler PA) Scotese Anthony C. (King of Prussia PA), HMG-COA reductase inhibitors.
  58. Regan John R. (Princeton NJ) Bruno Joseph G. (Sellersville PA) Neuenschwander Kent W. (Ambler PA) Kuhla Donald E. (Doylestown PA), HMG-COA reductase inhibitors.
  59. Vickers Stanley (Perkasie PA), HMG-CoA reductase inhibitor metabolites.
  60. Regan John R. (Princeton NJ) Neuenschwander Kent W. (Ambler PA), HMG-CoA reductase inhibitors.
  61. Smith Robert L. (Lansdale PA) Halczenko Wasyl (Hatfield PA) Hartman George D. (Lansdale PA) Stokker Gerald E. (Gwynedd Valley PA) Inamine Edward S. (Rahway NJ) Hensens Otto D. (Red Bank NJ) Houck Dav, HMG-CoA reductase inhibitors.
  62. Smith Robert L. ; Halczenko Wasyl ; Hartman George D. ; Stokker Gerald E. ; Inamine Edward S. ; Hensens Otto D. ; Houck David R. ; Lee Ta Jyh, HMG-CoA reductase inhibitors.
  63. Monaghan Richard L. (Somerset NJ) Alberts Alfred W. (Short Hills NJ) Hoffman Carl H. (Scotch Plains NJ) Albers-Schonberg George (Princeton NJ), Hypocholesteremic fermentation products and process of preparation.
  64. Cantrell John L. (Corvallis MT) Rudbach Jon A. (Hamilton MT), Immunological emulsion adjuvants for polysaccharide vaccines.
  65. Cantrell John L. (Corvallis MT), Immunological lipid emulsion adjuvant.
  66. Allison Anthony Clifford (London EN) Gregoriadis Gregory (Kenton EN), Immunological preparations.
  67. Ghyczy Miklos (Cologne DEX) Erds Adorjan (Cologne DEX) Heidemann Gnter (Geilenkirchen-Tripsrath DEX), Inflammation-preventing pharmaceutical composition of oral administration.
  68. Ghyczy Miklos (Cologne DEX) Erds Adorjan (Cologne DEX) Heidemann Gnter (Geilenkirchen-Tripsrath DEX) Ritzmann Gtz (Cologne DEX), Inflammation-preventing pharmaceutical composition of oral administration.
  69. Ghyczy Miklos (Cologne DEX) Erds Adorjan (Cologne DEX) Heidemann Gnter (Geilenkirchen-Tripsrath DEX) Ritzmann Gtz (Cologne DEX), Inflammation-preventing pharmaceutical composition of oral administration.
  70. Ghyczy, Miklos; Erdos, Adorjan; Heidemann, Gunter; Ritzmann, Gotz, Inflammation-preventing pharmaceutical composition of oral administration.
  71. Nerome Kuniaki (Tokyo JPX) Oya Akira (Tokyo JPX) Ohkuma Kunio (Kumamoto JPX) Inoue Atsuo (Funabashi JPX), Influenza vaccine.
  72. Oppenheim ; Richard Charles ; Marty ; Jennifer Joy ; Speiser ; Peter, Injectable compositions, nanoparticles useful therein, and process of manufacturing same.
  73. Kathawala Faizulla G. (Mountain Lakes NJ), Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof.
  74. Papahadjopoulos ; P. Demetrios, Large unilamellar vesicles (LUV) and method of preparing same.
  75. Miller Irving F. (Evanston IL) Djordjevich Ljubomir (Chicago IL), Lipid encapsulated hemoglobin cells.
  76. Fountain Michael W. (Plainsboro NJ) Weiss Steven J. (Lawrenceville NJ) Kearns John J. (Princeton NJ) Weiner Alan L. (Plainsboro NJ) Popescu Mircea C. (Plainsboro NJ), Lipid matrix carriers for use in drug delivery systems.
  77. Speiser Peter (Zurich CHX), Lipid nano-pellets as excipient system for perorally administered drugs.
  78. Steck Edgar A. (Silver Spring MD) Alving Carl R. (Washington DC), Liposome carriers in chemotherapy of leishmaniasis.
  79. Steck Edgar A. (Silver Spring MD) Alving Carl R. (Washington DC), Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives.
  80. Kelly Lawrence A. (Morris Plains NJ), Liposome drug delivery systems.
  81. Ash Philip S. (Colchester GB2) Hider Robert C. (St. Osyth GB2), Liposomes and their use in treating human or other mammalian patients.
  82. Allen Theresa M. (Edmonton CAX), Liposomes with enhanced circulation time.
  83. Terahara Akira (Hiromachi JPX) Tanaka Minoru (Hiromachi JPX), ML-236B Derivatives and their preparation.
  84. Morris Robert M. (Franklin IN), Magnetically-localizable, biodegradable lipid microspheres.
  85. Boyer Jean-Francois (73 rue des Jeux de Billes 78550 Houdan FRX), Medicine based on fenofibrate, and a method of preparing it.
  86. Deamer David W. (Woodland CA), Method for encapsulating materials into liposomes.
  87. Zolle Ilse (Lazarettgasse 14A Vienna 1090 OE), Method for incorporating substances into protein microspheres.
  88. Olukotun Adeove Y. (Hopewell NJ) Alexander John C. (Winnetka IL), Method for preventing a second heart attack employing an HMG CoA reductase inhibitor.
  89. Hunt C. Anthony (San Francisco CA) Papahadjopoulous Demetrios P. (Lafayette CA), Method for producing liposomes in selected size range.
  90. Widder Kenneth J. (Carboro NC) Senyei Andrew E. (Long Beach CA), Method of delivering a therapeutic agent to a target capillary bed.
  91. Sears Barry D. (5 Cleveland Rd. Marblehead MA 01945), Method of emulsifying cholesterol, cholesterol esters and triglyceride compounds.
  92. Papahadjopoulos Demetrios P. (78 Heathwood Williamsville NY 14221) Szoka ; Jr. Francis C. (375 Leroy Ave. Buffalo NY 14214), Method of encapsulating biologically active materials in lipid vesicles.
  93. Papahadjopoulos Demetrios P. (78 Heathwood Williamsville NY 14221) Szoka ; Jr. Francis C. (375 Leroy Ave. Buffalo NY 14214), Method of encapsulating biologically active materials in lipid vesicles.
  94. Mezei Michael (Halifax CAX) Nugent Fredric J. (Halifax CAX), Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV).
  95. Wretlind ; Karl A. J. ; Ljungberg ; Stellan ; Hakansson ; Ivan ; Ajaxon ; Bengt M., Method of enhancing the administration of pharmalogically active agents.
  96. Haynes Duncan H. (4051 Barbarossa Ave. Miami FL 33133), Method of inducing local anesthesia using microdroplets of a general anesthetic.
  97. Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Method of making nanoparticulate X-ray blood pool contrast agents using high molecular weight nonionic surfactants.
  98. Suzuki Akira (Takatsuki JA) Miura Hiroshi (Neyagawa JA) Matsuda Saburo (Kyoto JA) Ohsawa Takashi (Ibaragi JA), Method of preparing a controlled release liquid pharmaceutical composition.
  99. Sears Barry D. (43 Bay State Rd. Boston MA 02215), Method of preparing a controlled-release pharmaceutical preparation, and resulting composition.
  100. Boyer Jean-Francois (Houdan FRX), Method of preparing comtrolled release fenofibrate.
  101. MacDonald Robert C. (Evanston IL), Method of preparing giant size liposomes.
  102. Mosier Benjamin (5139 S. Braeswood Houston TX 77096), Method of preparing microspheres for intravascular delivery.
  103. Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Method of preparing nanoparticle compositions containing charged phospholipids to reduce aggregation.
  104. Kondo ; Sadao ; Nakano ; Hidehiko, Method of producing microcapsules and resulting product.
  105. Liversidge Gary G. (West Chester PA) Phillips Christopher P. (Brandamore PA) Cundy Kenneth C. (Belmont CA), Method to reduce particle size growth during lyophilization.
  106. Baurain Roger (Wezembeek BEX) Trouet Andre B. L. (Winksele BEX), Microcrystals comprising an active substance having an affinity for phospholipids, and at least one phospholipid, proces.
  107. Haynes Duncan H. (4051 Barbarossa Ave. Miami FL 33133), Microdroplets of water-insoluble drugs and injectable formulations containing same.
  108. Ohkawara Masaaki (Yokohama JPX) Miyahara Masayuki (Tama JPX) Ono Yoshitaka (Chiba JPX), Mono-core type microcapsules and process for producing them.
  109. Mezei Michael (Nova Scotia CAX), Multiphase liposomal drug delivery system.
  110. Cover William H. (Lansdale PA) Dabora Rebecca L. (Andover MA) Hong Anderson (Taipei WA TWX) Reeves Christopher (Mill Creek WA) Stieber Robert W. (Harrisonburg VA) Vinci Victor A. (Charlottesville VA), Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydr.
  111. Hansen Philip E. (Copenhagen DKX) Sorensen Anders R. (Herlev DKX), Nasal formulation and intranasal administration therewith.
  112. Ullrich John W. (Audubon PA) Neuenschwander Kent W. (Ambler PA) Regan John R. (Princeton NJ), Novel HMG-COA reductase inhibitors.
  113. Inamine Edward S. (Rahway NJ) Hensens Otto D. (Red Bank NJ) Houck David R. (Los Alamos NM) Lee Ta J. (Lansdale PA) Smith Robert L. (Lansdale PA) Halczenko Wasyl (Hatfield PA) Hartman George D. (Lansd, Novel HMG-CoA reductase inhibitors.
  114. Prugh John (Chalfont PA) Deana Albert A. (Lansdale PA) Rooney Clarence S. (Worcester PA), Novel HMG-CoA reductase inhibitors.
  115. Curtet Bernard (Marsanny la Cote FRX) Teillaud Eric (Talant FRX) Reginault Philippe (Fontaine les Dijon FRX), Novel dosage form of fenofibrate.
  116. Sasaki Masaomi (Shizuoka JPX) Hashimoto Mitsuru (Numazu JPX) Kawakami Tomiko (Tokyo JPX), Ortho-Bis (2-substituted azostyryl) benzene compounds.
  117. Szab Anna Z. (Budapest HUX) Gal Joszef (Budapest HUX) Mrmarosi Katalin (Budapest HUX) Sebestyn Gyula (Budapest HUX) Miholics Gizella (Budapest HUX) Kovcs Mrta (Budapest HUX), Pharmaceutical composition and process for the preparation thereof.
  118. Deboeck Arthur (Carolina PRX) Maes Paul (Carolina PRX) Baudier Phillipe R. (Carolina PRX), Pharmaceutical composition containing fenofibrate.
  119. Dingle John T. (Whittlesford GB2) Gordon John L. (Cambridge GB2) Jones Geraint (Macclesfield GB2) Knight Clive G. (Huntingdon GB2) Lowe John S. (Wilmslow GB2), Pharmaceutical compositions.
  120. Schmidt Dieter (Basel CHX), Pharmaceutical compositions for parenteral or local administration.
  121. Schmidt Dieter (Basel CHX), Pharmaceutical compositions for parenteral or local administration.
  122. Laruelle Claude,FRX, Pharmaceutical dosage formulations of fenofibrate and their applications.
  123. List Paul H. (Marburg DEX) Schmidt Peter C. (Marburg DEX) Steffens Klaus-Jrgen (Marburg DEX) Perschbacher Harald (Bad Homburg DEX) Kraemer Hans P. (Marburg DEX) Sedlacek Hans H. (Marburg DEX), Pharmaceutical formulation and process for its preparation.
  124. Muller Rainer H.,DEX ; Becker Robert,DEX ; Kruss Bernd,DEX ; Peters Katrin,DEX, Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of.
  125. Dietl Hans (Eichendorffstrasse 33 Bad Aibling DEX 8202), Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production.
  126. Schrank Jrg (Riehen CHX) Steffen Hans (Arisdorf CHX), Pharmaceutical preparations.
  127. Haynes Duncan H. (4051 Barbarossa Ave. Miami FL 33133), Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs.
  128. Haynes Duncan H. (4051 Barbarossa Ave. Miami FL 33133), Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs.
  129. Karanewsky Donald S. (East Windsor NJ) Biller Scott A. (Ewing NJ) Gordon Eric M. (Pennington NJ), Phosphorous-containing HMG-CoA reductase inhibitors, new intermediates and method.
  130. Karanewsky Donald S. (East Windsor NJ) Biller Scott A. (Ewing NJ) Gordon Eric M. (Pennington NJ), Phosphorus-containing HMG-COA reductase inhibitors.
  131. Karanewsky Donald S. (East Windsor NJ) Badia Michael C. (Lawrenceville NJ) Biller Scott A. (Ewing NJ) Gordon Eric M. (Pennington NJ) Sofia Michael J. (Lawrenceville NJ), Phosphorus-containing HMG-COA reductase inhibitors, new intermediates and method.
  132. Karanewsky Donald S. (Robbinsville NJ), Phosphorus-containing HMG-CoA reductase inhibitor compounds.
  133. Robl Jeffrey A. (Holland PA), Phosphorus-containing HMG-CoA reductase inhibitors.
  134. Karanewsky Donald S. (East Windsor NJ) Badia Michael C. (Lawrenceville NJ) Biller Scott A. (Ewing NJ) Gordon Eric M. (Pennington NJ) Sofia Michael J. (Lawrenceville NJ), Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method.
  135. Postle Stephen R. (Brentwood GB2) Psaila Alexander (Chelmsford GB2), Photographic silver halide material containing a dye filter or a dye anti-halation layer.
  136. Endo Akira (Tokyo JA) Kuroda Masao (Tokyo JA) Terahara Akira (Tokyo JA) Tsujita Yoshio (Tokyo JA) Tamura Chihiro (Tokyo JA), Physiologically active substances.
  137. Los Mario A. (Buenos Aires ARX), Potentiated sulfonamide injectable preparation.
  138. Huang Leaf (Knoxville TN), Preparation of solid core liposomes.
  139. Growdon John H. (Brookline MA) Wurtman Richard J. (Boston MA), Process and composition for treating disorders by administering isoxsurpine and choline.
  140. Swank Thomas F. (Chelmsford MA) Waack Richard (Wayland MA), Process for dispersing sensitizing dyes.
  141. Morishita Masataka (Shizuoka JA) Inaba Yoshihito (Shizuoka JA) Fukushima Mitsuru (Shizuoka JA) Hattori Yoshinori (Shizuoka JA) Kobari Sadami (Shizuoka JA) Matsuda Tetsuo (Shizuoka JA), Process for encapsulation of medicaments.
  142. Taylor James L. (Naperville IL), Process for making lipid membrane structures.
  143. Gopadi M. Venkatesh ; Nageswara R. Palepu GB, Process for manufacturing bite-dispersion tablets.
  144. Samejima Masayoshi (Minoh JPX) Hirata Goichi (Yawata JPX), Process for preparing ethylcellulose microcapsules.
  145. Green Richard,GBX ; Kearney Patrick,GBX, Process for preparing fast dispersing solid oral dosage form.
  146. Leclef Brigitte (Brussels BEX) Cerfontaine Patrick (Brussels BEX) Nicolas Jean-Marie (Overijse BEX) Wantier Henri (Dour BEX) Trouet Andr (Winksele Herent BEX), Process for preparing lipid microparticles.
  147. Jizomoto Hiroaki (Osaka JPX), Process for preparing liposome compositions.
  148. Engh Kevin R. ; Qiu Yihong ; Reiland Thomas L., Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption.
  149. Bosch H. William (Bryn Mawr PA) Marcera Donna M. (Collegeville PA) Mueller Ronald L. (Downingtown PA) Swanson Jon R. (Macungie PA) Mishra Dinesh S. (Harleysville PA), Process for preparing therapeutic compositions containing nanoparticles.
  150. Marchetti Enzo (Rome ITX) Bucciarelli Umberto (Rome ITX), Process for the extemporaneous preparation of liposomes.
  151. Augart Helmut (Waldkirch DEX), Process for the manufacture of a pharmaceutical composition with a retarded liberation of active material.
  152. Schneider ; Michel, Process for the preparation of liposomes.
  153. Duclos Roselyne,FRX ; Terracol Didier,FRX, Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions.
  154. Terracol Didier,FRX ; Duclos Roselyne,FRX, Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions.
  155. End Lutz (Mannheim DEX) Horn Dieter (Heidelberg DEX) Lueddecke Erik (Mutterstadt DEX), Production of fine particle dye or drug preparations.
  156. Haynes Duncan H. (Miami FL), Propofol microdroplet formulations.
  157. Chucholowski Alexander (Ypsilanti MI), Pyridine di-mevalono-lactones as inhibitors of cholesterol biosynthesis.
  158. Hill Randal M. (Midland MI) Snow Steven A. (Sanford MI), Silicone vesicles and entrapment.
  159. Wunderlich Jens-Christian,DEX ; Schick Ursula,DEX ; Werry Jurgen,DEX ; Freidenreich Jurgen,DEX, Sol-controlled thermocolloid matrix based on gelatin for oral sustained-release form.
  160. Chagnon Mark S. (Pelham NH) Ferris John R. (Newburyport MA) Hamilton Tracy J. (Salem NH) Rudd Edwin A. (Salem NH) Carter Michelle J. (Derry NH), Solid care therapeutic compositions and methods for making same.
  161. Amselem Shimon (Rehovot ILX) Friedman Doron (Carmei Yosef ILX), Solid fat nanoemulsions.
  162. Amselem Shimon (Rehovot ILX) Friedman Doron (Carmei Yosef ILX), Solid fat nanoemulsions as drug delivery vehicles.
  163. Westesen Kirsten,DEX ; Siekmann Britta,DEX, Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof.
  164. Pace, Gary W.; Mishra, Awadesh K.; Snow, Robert A.; Parikh, Indu; Guivarc'h, Pol-Henri W., Spray drying process and compositions of fenofibrate.
  165. Alberts Alfred W. (Princeton NJ) Berger Gregory D. (Belle Meade NJ) Bergstrom James D. (Neshanic Station NJ), Squalene synthetase inhibitors.
  166. Abra Robert (San Francisco CA) Szoka Francis C. (San Francisco CA), Stabilized liposome/amphotericin composition and method.
  167. Ghyczy Miklos (Cologne DEX) Ritzmann Gtz (Cologne DEX) Erds Adorjan (Cologne DEX) Etschenberg Eugen (Cologne DEX), Stabilized parenterally administrable solutions.
  168. Kabadi Mohan B. (Marlboro NJ) Vivilecchia Richard V. (Rockaway NJ), Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound.
  169. Lenk Robert P. (Lambertville NJ) Fountain Michael W. (Griggstown NJ) Janoff Andrew S. (Yardley PA) Popescu Mircea C. (Plainsboro NJ) Weiss Steven J. (Hightstown NJ) Ginsberg Richard S. (Monroe Townsh, Stable plurilamellar vesicles.
  170. Weiner Murray (8915 Spooky Ridge La. Cincinnati OH 45242) Gersonde Klaus (Preusweg 69 D-5100 Aachen DEX), Storage-stable lipid vesicles and method of preparation.
  171. Regan John R. (Princeton NJ) Bruno Joseph G. (Sellersville PA) Neuenschwander Kent W. (Ambler PA), Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors.
  172. Regan John R. (Princeton NJ) Neuenschwander Kent E. (Ambler PA), Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors.
  173. Regan John R. (Princeton NJ) Neuenschwander Kent W. (Ambler PA), Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors.
  174. Wong Sui-Ming (Collegeville PA) Newington Ian M. (Hazlemere GB2) Liversidge Elaine M. (West Chester PA) McIntire Gregory L. (West Chester PA) Pitt Alan R. (Sandridge GBX) Shaw Jack M. (Aberdeen MD), Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions.
  175. Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
  176. Haynes Duncan H. (Miami FL), Sustained release delivery of water soluble bio-molecules and drugs using phosphokipid-coated microcrystals, microdrople.
  177. Haynes Duncan H. (4051 Barbarossa Ave. Miami FL 33133), Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdrople.
  178. Pawan Seth, Sustained release pharmaceutical composition free of food effect.
  179. Alam Abu S. (Westerville OH) Eichel Herman J. (Columbus OH), Sustained release pharmaceutical formulation.
  180. Kerc Janez,SIX ; Rebic Ljubomira Barbara,SIX ; Kofler Bojan,SIX, Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application.
  181. Reller Herbert H. (Cincinnati OH), Topical anti-inflammatory composition.
  182. Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Use of charged phospholipids to reduce nanoparticle aggregation.
  183. Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Use of ionic cloud point modifiers to prevent particle aggregation during sterilization.
  184. Gerber Jay D. (Lincoln NE), Vaccine formulation.
  185. Fukushima Tsunekazu (Hyogo JPX) Emoto Hiroshi (Osaka JPX) Kagitani Yoshio (Nara JPX) Yokoyama Kazumasa (Osaka JPX) Nishida Masayuki (Osaka JPX) Suyama Tadakazu (Kyoto JPX), Water soluble drug complex and method for production of same.
  186. Amidon Gordon L. ; Crison John R., Water soluble pharmaceutical coating and method for producing coated pharmaceuticals.
  187. Sears Barry (Marblehead MA) Yesair David W. (Newbury MA), Xenobiotic delivery vehicles, method of forming them and method of using them.
  188. Roth Bruce D. (Ann Arbor MI), [R-(R*R*)]-2-(4-fluorophenyl)-bd 상세보기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트